Spots Global Cancer Trial Database for radioimmunotherapy
Every month we try and update this database with for radioimmunotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades | NCT01693159 | Pain | ECA Standard topica... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma | NCT01130194 | Follicular Lymp... | Combination of ... | 18 Years - 80 Years | St. Louis University | |
| Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | NCT00434629 | B-cell Lymphoma Non-Hodgkin's L... | Bexxar | 18 Years - 75 Years | University of Pennsylvania | |
| Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab | NCT00996593 | Lymphoma, Non-H... | Anti-B1 Antibod... | 18 Years - | GlaxoSmithKline | |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00992992 | Lymphoma, Mantl... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Expanded Access Study of Iodine-131 Anti-B1 Antibody | NCT00022958 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00992992 | Lymphoma, Mantl... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | NCT01242943 | Patients With C... | 131I-L19SIP Rad... | 18 Years - 75 Years | Philogen S.p.A. | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | NCT00992758 | Lymphoma, Non-H... | Iodine-131 Anti... | 18 Years - | GlaxoSmithKline | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | NCT00022880 | Chronic Lymphoc... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Treatment Selection According to Skin Reaction to Cetuximab | NCT01472653 | Head and Neck C... | cisplatin radiotherapy cetuximab | 18 Years - 70 Years | Institute of Oncology Ljubljana | |
| Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy | NCT01192087 | Adenoid Cystic ... | Cetuximab | 18 Years - 70 Years | Heidelberg University | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| Zevalin-beam for Aggressive Lymphoma | NCT00491491 | Non-Hodgkin's L... | ibritumomab tiu... BEAM chemothera... | 18 Years - 70 Years | Sheba Medical Center | |
| 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC) | NCT01124812 | Non Small Cell ... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | NCT00434629 | B-cell Lymphoma Non-Hodgkin's L... | Bexxar | 18 Years - 75 Years | University of Pennsylvania | |
| Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | NCT00168727 | Lymphoma, Non-H... Lymphoma, Low-G... | ibritumomab tiu... | 18 Years - | Biogen | |
| Treatment Selection According to Skin Reaction to Cetuximab | NCT01472653 | Head and Neck C... | cisplatin radiotherapy cetuximab | 18 Years - 70 Years | Institute of Oncology Ljubljana | |
| Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | NCT02657447 | Non-Hodgkin Lym... | Betalutin with ... Betalutin with ... | 18 Years - | Nordic Nanovector | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | NCT00992758 | Lymphoma, Non-H... | Iodine-131 Anti... | 18 Years - | GlaxoSmithKline | |
| Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies | NCT01224821 | Lymphoma, Non-H... | Tositumomab (An... | 18 Years - | GlaxoSmithKline | |
| Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab | NCT00996593 | Lymphoma, Non-H... | Anti-B1 Antibod... | 18 Years - | GlaxoSmithKline | |
| A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer | NCT01240720 | Cancer | 131I-F16SIP Rad... | 18 Years - | Philogen S.p.A. | |
| Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer | NCT00860860 | Colorectal Neop... | TF2 IMP-288 labeled... | 18 Years - | Radboud University Medical Center | |
| Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma | NCT00996996 | Lymphoma, Non-H... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP | NCT00022932 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - 80 Years | Corixa Corporation | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma | NCT00022893 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma | NCT00996996 | Lymphoma, Non-H... | Tositumomab and... | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | NCT00022945 | Mantle Cell Lym... | Iodine-131 Anti... Cyclophosphamid... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement | NCT00022906 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement | NCT00022906 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma | NCT02581878 | Lymphoma, Non-H... | BAY1862864 | 18 Years - | Bayer | |
| Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma | NCT00268983 | Lymphoma, Non-H... | Tositumomab and... Rituximab | 18 Years - | GlaxoSmithKline | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma | NCT00302757 | Non-Hodgkin Lym... | Radioimmunother... allogeneic hema... | 18 Years - 70 Years | University Hospital Tuebingen | |
| 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors | NCT01125085 | Brain Metastase... | 131I-L19SIP Rad... | 18 Years - | Philogen S.p.A. | |
| Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy | NCT01151358 | Follicular Lymp... | 18 Years - | University Hospital, Saarland | ||
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma | NCT00022893 | Non-Hodgkin's L... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | NCT00514475 | Mantle Cell Lym... | 90Y-ibritumomab... | 18 Years - 65 Years | Oslo University Hospital | |
| Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | NCT01242943 | Patients With C... | 131I-L19SIP Rad... | 18 Years - 75 Years | Philogen S.p.A. | |
| Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | NCT00022880 | Chronic Lymphoc... | Iodine-131 Anti... | 18 Years - | Corixa Corporation | |
| Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy | NCT01151358 | Follicular Lymp... | 18 Years - | University Hospital, Saarland | ||
| Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | NCT01521611 | Acute Leukaemia Chronic Leukaem... Myeloma Lymphoma | Targeted radiot... | 18 Years - 75 Years | University Hospital Southampton NHS Foundation Trust |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
